HUP0401986A2 - LHRH antagonistát tartalmazó injekciós oldat és eljárás az előállítására - Google Patents

LHRH antagonistát tartalmazó injekciós oldat és eljárás az előállítására

Info

Publication number
HUP0401986A2
HUP0401986A2 HU0401986A HUP0401986A HUP0401986A2 HU P0401986 A2 HUP0401986 A2 HU P0401986A2 HU 0401986 A HU0401986 A HU 0401986A HU P0401986 A HUP0401986 A HU P0401986A HU P0401986 A2 HUP0401986 A2 HU P0401986A2
Authority
HU
Hungary
Prior art keywords
preparation
lhrh
lhrh antagonist
injection solution
lhrh antagonists
Prior art date
Application number
HU0401986A
Other languages
English (en)
Inventor
Werner Sarlikiotis
Horst Bauer
Matthias Rischer
Jürgen Engel
Frank Güthlein
Dominique Stefano
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of HUP0401986A2 publication Critical patent/HUP0401986A2/hu
Publication of HUP0401986A3 publication Critical patent/HUP0401986A3/hu
Publication of HU230992B1 publication Critical patent/HU230992B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány LHRH antagonisták olyan, vizes injekciós oldatairavonatkozik, amelyek az LHRH antagonistán, például cetrorelixen kívülszerves, fiziológiásan elfogadható savat és adott esetben felületaktívanyagot és térfogatnövelő szert tartalmaznak. Az LHRH antagonistákoldhatósága jelentősen megnő, és így nagyobb koncentrációjú oldatokállíthatók elő a hatóanyagokból. Javul a hatóanyagokbiohasznosíthatósága; valamint szignifikáns mértékben csökken az LHRHantagonisták aggregációs hajlama. Ó
HU0401986A 2001-11-26 2002-11-15 LHRH antagonistát tartalmazó injekciós oldat HU230992B1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10157628.5 2001-11-26
DE10157628A DE10157628A1 (de) 2001-11-26 2001-11-26 Injektionslösung eines LHRH-Antagonisten
PCT/EP2002/012798 WO2003045419A1 (de) 2001-11-26 2002-11-15 Injektionslösung eines lhrh-antagonisten

Publications (3)

Publication Number Publication Date
HUP0401986A2 true HUP0401986A2 (hu) 2005-01-28
HUP0401986A3 HUP0401986A3 (en) 2012-09-28
HU230992B1 HU230992B1 (hu) 2019-08-28

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401986A HU230992B1 (hu) 2001-11-26 2002-11-15 LHRH antagonistát tartalmazó injekciós oldat

Country Status (33)

Country Link
EP (1) EP1448221B1 (hu)
JP (1) JP4343693B2 (hu)
KR (1) KR100936636B1 (hu)
CN (1) CN100404068C (hu)
AR (1) AR037424A1 (hu)
AT (1) ATE350050T1 (hu)
AU (1) AU2002365504B2 (hu)
BR (1) BRPI0214412B8 (hu)
CO (1) CO5580793A2 (hu)
CY (1) CY1106401T1 (hu)
DE (2) DE10157628A1 (hu)
DK (1) DK1448221T3 (hu)
EA (1) EA010787B1 (hu)
ES (1) ES2276970T3 (hu)
GE (1) GEP20063861B (hu)
HK (1) HK1073078A1 (hu)
HR (1) HRP20040587B1 (hu)
HU (1) HU230992B1 (hu)
IL (2) IL161894A0 (hu)
IS (1) IS2725B (hu)
ME (1) ME00499B (hu)
MX (1) MXPA04005018A (hu)
NO (1) NO333364B1 (hu)
NZ (1) NZ533712A (hu)
PL (1) PL206199B1 (hu)
PT (1) PT1448221E (hu)
RS (1) RS51408B (hu)
RU (1) RU2322969C2 (hu)
SI (1) SI1448221T1 (hu)
TW (1) TWI312283B (hu)
UA (1) UA81612C2 (hu)
WO (1) WO2003045419A1 (hu)
ZA (1) ZA200404051B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
US8999383B2 (en) 2008-05-07 2015-04-07 Merrion Research Iii Limited Compositions of GnRH related compounds and processes of preparation
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
KR20140026354A (ko) 2011-01-07 2014-03-05 메리온 리서치 Ⅲ 리미티드 경구 투여용 철의 제약 조성물
CN103690560B (zh) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 一种转化糖电解质注射液药物组合物及其制备方法
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
RU2614234C2 (ru) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция на основе 3-(4-Метилимидазол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства
AU2018212806A1 (en) * 2017-01-30 2019-07-18 Antev Limited A composition comprising at least one GnRH antagonist
MD3811927T2 (ro) 2019-10-24 2022-03-31 Sun Pharmaceutical Ind Ltd O formă de dozaj parenterală stabilă de acetat de cetrorelix

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
EP1214086A2 (en) * 1999-09-23 2002-06-19 Zentaris AG Method for the therapeutic management of endometriosis and fallopian tube obstruction
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung

Also Published As

Publication number Publication date
HU230992B1 (hu) 2019-08-28
BRPI0214412B8 (pt) 2021-05-25
TW200300352A (en) 2003-06-01
DE50209193D1 (de) 2007-02-15
ES2276970T3 (es) 2007-07-01
IS7251A (is) 2004-05-06
HK1073078A1 (en) 2005-09-23
TWI312283B (en) 2009-07-21
EP1448221A1 (de) 2004-08-25
RS44904A (en) 2006-10-27
CO5580793A2 (es) 2005-11-30
JP2005510544A (ja) 2005-04-21
EA010787B1 (ru) 2008-10-30
DE10157628A1 (de) 2003-06-12
IS2725B (is) 2011-03-15
CN100404068C (zh) 2008-07-23
NO333364B1 (no) 2013-05-13
PT1448221E (pt) 2007-03-30
ME00499B (me) 2011-10-10
SI1448221T1 (sl) 2007-06-30
RU2004119821A (ru) 2005-04-20
KR100936636B1 (ko) 2010-01-14
AU2002365504A1 (en) 2003-06-10
NZ533712A (en) 2006-01-27
BR0214412A (pt) 2004-09-14
GEP20063861B (en) 2006-06-26
WO2003045419A1 (de) 2003-06-05
IL161894A (en) 2014-05-28
HUP0401986A3 (en) 2012-09-28
PL369548A1 (en) 2005-05-02
JP4343693B2 (ja) 2009-10-14
NO20042449L (no) 2004-06-11
HRP20040587B1 (en) 2008-01-31
HRP20040587A2 (en) 2004-10-31
ZA200404051B (en) 2005-05-25
EP1448221B1 (de) 2007-01-03
EA200400742A1 (ru) 2004-12-30
UA81612C2 (ru) 2008-01-25
DK1448221T3 (da) 2007-03-19
ATE350050T1 (de) 2007-01-15
CN1592630A (zh) 2005-03-09
MXPA04005018A (es) 2004-08-11
IL161894A0 (en) 2005-11-20
KR20040058312A (ko) 2004-07-03
BRPI0214412B1 (pt) 2016-01-05
RU2322969C2 (ru) 2008-04-27
PL206199B1 (pl) 2010-07-30
RS51408B (sr) 2011-02-28
AR037424A1 (es) 2004-11-10
CY1106401T1 (el) 2011-10-12
AU2002365504B2 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
HUP0401986A2 (hu) LHRH antagonistát tartalmazó injekciós oldat és eljárás az előállítására
CA2411754A1 (en) 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid and compositions for delivering active agents
CY1112510T1 (el) Φαρμακευτικο παρασκευασμα υπο τη μορφη παστας το οποιο περιεχει ενα ασταθες στα οξεα δραστικο συστατικο
CA2448035A1 (en) New pharmaceutical composition
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
KR970704472A (ko) 수성 리스페리돈 제제(aqueous risperidone formulations)
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
ATE429416T1 (de) Cyanophenoxy-carbonsäuren und zusammensetzungen für die freisetzung aktiver substanzen
EA200400777A1 (ru) Фармацевтические композиции соединения платины
TR200002812T2 (tr) Efervesan formülasyonları.
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
SE0100566D0 (sv) Compounds
CO5540279A2 (es) Formulacion liofilitada de 2-metil-tieno-benzodiazepina
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
HUP0202324A2 (hu) Prukaloprid orális oldat
SE0101692D0 (sv) Compounds
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
PT1150660E (pt) Formulacao farmaceutica efervescente contendo metamizole
HUP0303141A2 (hu) Gyógyszerkészítmények és eljárás az előállításukra
MXPA05004842A (es) Formulacion oromucosal y proceso para su preparacion.
RU2001108785A (ru) Препарат интерферона

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ZENTARIS GMBH, DE

Free format text: FORMER OWNER(S): ZENTARIS GMBH, DE

GB9A Succession in title

Owner name: ZENTARIS IVF GMBH, DE

Free format text: FORMER OWNER(S): ZENTARIS GMBH, DE; AETERNA ZENTARIS GMBH, DE; ZENTARIS GMBH, DE

HC9A Change of name, address

Owner name: ZENTARIS IVF GMBH, DE

Free format text: FORMER OWNER(S): ZENTARIS GMBH, DE; AETERNA ZENTARIS GMBH, DE; ZENTARIS GMBH, DE